58 related articles for article (PubMed ID: 38646637)
1. Vaccines for preventing typhoid fever.
Milligan R; Paul M; Richardson M; Neuberger A
Cochrane Database Syst Rev; 2018 May; 5(5):CD001261. PubMed ID: 29851031
[TBL] [Abstract][Full Text] [Related]
2. Vaccines for preventing typhoid fever.
Anwar E; Goldberg E; Fraser A; Acosta CJ; Paul M; Leibovici L
Cochrane Database Syst Rev; 2014 Jan; (1):CD001261. PubMed ID: 24385413
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis.
Mohamed Taha A; Abouelmagd K; Mahmoud AM; Elkasaby MH; Nguyen D; Ahmed R; Patel P; Bonilla-Aldana DK; Luna C; Rodriguez-Morales AJ
Front Microbiol; 2024; 15():1385834. PubMed ID: 38646637
[TBL] [Abstract][Full Text] [Related]
4. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: Safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine.
Medise BE; Soedjatmiko S; Rengganis I; Gunardi H; Sekartini R; Koesno S; Satari HI; Hadinegoro SR; Yang JS; Excler JL; Sahastrabuddhe S; Puspita M; Sari RM; Bachtiar NS
PLoS One; 2019; 14(2):e0211784. PubMed ID: 30759132
[TBL] [Abstract][Full Text] [Related]
5. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: Safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
Int J Infect Dis; 2020 Apr; 93():102-107. PubMed ID: 32004693
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.
Tamrakar D; Poudel P; Thapa P; Singh S; Khadgi A; Thapa S; Tamrakar R; Shrestha A; Madhup S; Rai GK; Gupta BP; Saluja T; Sahastrabuddhe S; Shrestha R
Hum Vaccin Immunother; 2024 Dec; 20(1):2301631. PubMed ID: 38189360
[TBL] [Abstract][Full Text] [Related]
7. A randomized, observer-blind, controlled phase III clinical trial assessing safety and immunological non-inferiority of Vi-diphtheria toxoid versus Vi-tetanus toxoid typhoid conjugate vaccine in healthy volunteers in eastern Nepal.
Chaudhary S; Shah GS; Bhatta NK; Poudel P; Rai B; Uranw S; Tripathi PM; Khanal B; Ghimire A; Rai N; Gupta BP; Vemula S; Wartel TA; Sahastrabuddhe S; Saluja T
Hum Vaccin Immunother; 2023 Dec; 19(1):2203634. PubMed ID: 37128723
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, Multicenter, Randomized, Controlled Trial to Evaluate Immune Equivalence and Safety of Multidose and Single-dose Formulations of Vi-DT Typhoid Conjugate Vaccine in Healthy Filipino Individuals 6 Months to 45 Years of Age.
Carlos JC; Tadesse BT; Borja-Tabora C; Alberto E; Ylade MC; Sil A; Kim DR; Ahn HS; Yang JS; Lee JY; Kim MS; Park J; Kwon SY; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Reg Health West Pac; 2022 Jul; 24():100484. PubMed ID: 35664443
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.
Shakya M; Voysey M; Theiss-Nyland K; Colin-Jones R; Pant D; Adhikari A; Tonks S; Mujadidi YF; O'Reilly P; Mazur O; Kelly S; Liu X; Maharjan A; Dahal A; Haque N; Pradhan A; Shrestha S; Joshi M; Smith N; Hill J; Clarke J; Stockdale L; Jones E; Lubinda T; Bajracharya B; Dongol S; Karkey A; Baker S; Dougan G; Pitzer VE; Neuzil KM; Shrestha S; Basnyat B; Pollard AJ;
Lancet Glob Health; 2021 Nov; 9(11):e1561-e1568. PubMed ID: 34678198
[TBL] [Abstract][Full Text] [Related]
11. A
Jones E; Jin C; Stockdale L; Dold C; Pollard AJ; Hill J
Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34203328
[TBL] [Abstract][Full Text] [Related]
12. Typhoid fever infection - Antibiotic resistance and vaccination strategies: A narrative review.
Masuet-Aumatell C; Atouguia J
Travel Med Infect Dis; 2021; 40():101946. PubMed ID: 33301931
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of Vi-DT conjugate vaccine among 6-23-month-old children: Phase II, randomized, dose-scheduling, observer-blind Study.
Capeding MR; Sil A; Tadesse BT; Saluja T; Teshome S; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Chinaworapong S; Park J; Jo SK; Chon Y; Yang SY; Ryu JH; Cheong I; Shim KY; Lee Y; Kim H; Lynch JA; Kim JH; Excler JL; Wartel TA; Sahastrabuddhe S
EClinicalMedicine; 2020 Oct; 27():100540. PubMed ID: 33150320
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
